Trials / Terminated
TerminatedNCT04679350
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous(IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- ImmuneMed, Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
To explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection
Detailed description
A Multi center, Randomized, Double-blind, Parallel design
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | hzVSF-v13 | Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb) |
| DRUG | Placebo (Normal saline solution) | Dosage form: 0.9% NaCl solution Frequency: Dose at Day 1, 3, 7 |
Timeline
- Start date
- 2021-03-18
- Primary completion
- 2022-11-30
- Completion
- 2022-12-30
- First posted
- 2020-12-22
- Last updated
- 2024-02-15
Locations
3 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04679350. Inclusion in this directory is not an endorsement.